ArticleLaryngoscope investigative otolaryngology2026
Blue-Laser Posterior Nasal Neurolysis via Dual Layer Nerve Modulation for Chronic Rhinitis.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic rhinitis (CR) may be allergic (AR), nonallergic (NAR), or mixed, and depending on the etiology and severity, patients experience various degrees of rhinorrhea, obstruction, itching, and sneezing. Chronic AR is estimated to impact over 26.3% of the people in Taiwan. Inferior turbinate reduction can improve nasal obstruction symptoms, and posterior nasal nerve neurolysis can reduce symptoms caused by neurogenic hypersecretion. Blue-laser posterior nasal neurolysis via dual-layer nerve modulation provides a precise operation for chronic AR. Methods: In this retrospective study, conducted at Shuang Ho Hospital in 2025, we compared the efficacy and safety of blue-laser inferior turbinate reduction (BITR) combined with blue-laser posterior nasal nerve neurolysis (BPN3). In total, 42 adult patients with CR who had not responded adequately to at least 3 months of drug therapy (≥ 3 months) were included. The primary outcomes were the 24-h reflective Total Nasal Symptoms Score (rTNSS) and the Nasal Obstruction Symptoms Evaluation (NOSE) scale score, which were compared and analyzed at the baseline, and 1 and 6 months postoperatively. Results: At 1 month, all patients exhibited significant improvements. Mean rTNSS had decreased from 7.9 ± 2.1 to 1.7 ± 1.6 (-78.5%) and NOSE scores improved from 69.3 ± 11.4 to 7.0 ± 6.5 (-89.9%). At 6 months, the mean rTNSS had decreased from 7.9 ± 2.1 to 1.9 ± 1.8 (-76.0%) and NOSE scores had improved from 69.3 ± 11.4 to 6.6 ± 5.3 (-92.0%). Overall, no serious complications occurred during the study period. Conclusions: BPN3 combined with inferior turbinate reduction provides superior symptom relief, particularly for rhinorrhea, with excellent safety and tolerability. This dual layer nerve modulation operation offers a promising minimally invasive treatment for medication-refractory chronic AR. Level of Evidence: IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.